Zoetis Inc. $ZTS Shares Sold by United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 95.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,600 shares of the company’s stock after selling 251,749 shares during the period. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Zoetis were worth $834,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of ZTS. Vanguard Group Inc. boosted its stake in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after buying an additional 5,474,210 shares during the last quarter. J. Stern & Co. LLP grew its position in shares of Zoetis by 12,431.2% during the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after buying an additional 23,877,416 shares in the last quarter. State Street Corp increased its stake in shares of Zoetis by 0.8% in the fourth quarter. State Street Corp now owns 19,796,891 shares of the company’s stock worth $2,490,845,000 after buying an additional 149,382 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Zoetis by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after buying an additional 189,235 shares during the last quarter. Finally, Norges Bank acquired a new stake in Zoetis in the fourth quarter valued at $734,425,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS stock opened at $73.64 on Friday. The stock’s 50 day simple moving average is $76.30 and its 200 day simple moving average is $99.01. Zoetis Inc. has a 12-month low of $71.45 and a 12-month high of $160.48. The firm has a market cap of $30.43 billion, a P/E ratio of 12.13, a P/E/G ratio of 1.28 and a beta of 0.74. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the previous year, the company posted $1.76 earnings per share. The firm’s revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.19 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. Zoetis’s payout ratio is 34.93%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ZTS shares. Citigroup reduced their price objective on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Piper Sandler dropped their target price on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, August 10th. Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Stifel Nicolaus reduced their price target on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research report on Friday, June 26th. Finally, William Blair reiterated a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $109.62.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.